Among the many medical and therapeutic applications of psychedelics being explored in labs and boardrooms today, Alzheimer’s disease has maintained a relatively low profile. But that may be changing, thanks in part to a review article published last summer in Frontiers in Synaptic Neuroscience.1 “We have been stunned by the popularity of our article on the Frontiers platform…
